{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T07:24:11Z","timestamp":1786951451566,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40263-026-01306-8","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:11:42Z","timestamp":1782198702000},"page":"1179-1184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5994-2970","authenticated-orcid":false,"given":"Antonio","family":"Alc\u00e1ntara Montero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"1306_CR1","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.21873\/anticanres.15971","volume":"42","author":"A Avallone","year":"2022","unstructured":"Avallone A, Bimonte S, Cardone C, Cascella M, Cuomo A. Pathophysiology and therapeutic perspectives for chemotherapy-induced peripheral neuropathy. Anticancer Res. 2022;42:4667\u201378. https:\/\/doi.org\/10.21873\/anticanres.15971.","journal-title":"Anticancer Res"},{"key":"1306_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.pmn.2025.01.007","volume":"26","author":"AC Jesus Palma","year":"2025","unstructured":"Jesus Palma AC, Antunes CR, Barreto ESR, Alencar VB, Souza AKDN, Mathias CMC, et al. Pharmacological treatment of chemotherapy-induced neuropathy: a systematic review of randomized clinical trials. Pain Manag Nurs. 2025;26:249\u201363. https:\/\/doi.org\/10.1016\/j.pmn.2025.01.007.","journal-title":"Pain Manag Nurs"},{"key":"1306_CR3","doi-asserted-by":"publisher","unstructured":"D'Souza RS, Saini C, Hussain N, Javed S, Prokop L, Her YF. Global estimates of prevalence of chronic painful neuropathy and moderate-to-severe neuropathy among patients with chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis of data from 29 countries between 2000 and 2024. Reg Anesth Pain Med. 2025. https:\/\/doi.org\/10.1136\/rapm-2024-106229","DOI":"10.1136\/rapm-2024-106229"},{"key":"1306_CR4","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S577002","volume":"19","author":"CM Lam","year":"2026","unstructured":"Lam CM, Robinson CL, Aiyer R, Mata R, Xie K, Slitzky M, et al. Review of physiology, pathology, and pharmacology of voltage-gated sodium channels in regards to the potential role of NaV 1.8 selective agonist, Suzetrigine, for chronic pain management. J Pain Res. 2026;19:577002. https:\/\/doi.org\/10.2147\/JPR.S577002.","journal-title":"J Pain Res"},{"key":"1306_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-026-01472-w","volume":"30","author":"A Abd-Elsayed","year":"2026","unstructured":"Abd-Elsayed A, Hashimoto N, Reilly M, Kohr D, Sahin MZ. Selective NaV1.8 inhibition for pain management: current evidence and future potential of Suzetrigine. Curr Pain Headache Rep. 2026;30:35. https:\/\/doi.org\/10.1007\/s11916-026-01472-w.","journal-title":"Curr Pain Headache Rep"},{"key":"1306_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2025.1642306","volume":"6","author":"N Dong","year":"2025","unstructured":"Dong N, Lin T. Innate immunity in chemotherapy-induced peripheral neuropathy: recent advances. Front Pain Res (Lausanne). 2025;6:1642306. https:\/\/doi.org\/10.3389\/fpain.2025.1642306.","journal-title":"Front Pain Res (Lausanne)"},{"key":"1306_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2174\/0127724328314214240829181006","volume":"20","author":"J Yu","year":"2025","unstructured":"Yu J, Fu Y, Xu W, Ding RB, Bao J. Insights into the pathogenesis and treatment of chemotherapy-induced neuropathy: a focus on oxidative stress and neuroinflammation. Curr Rev Clin Exp Pharmacol. 2025;20:98\u2013102. https:\/\/doi.org\/10.2174\/0127724328314214240829181006.","journal-title":"Curr Rev Clin Exp Pharmacol"},{"key":"1306_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/01480545.2026.2624421","volume":"49","author":"D Ghosh","year":"2026","unstructured":"Ghosh D, Karati D. Neurotoxicity of chemotherapeutic agents: mechanisms and mitigation strategies. Drug Chem Toxicol. 2026;49:439\u201352. https:\/\/doi.org\/10.1080\/01480545.2026.2624421.","journal-title":"Drug Chem Toxicol"},{"key":"1306_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2026.1717395","volume":"7","author":"WLDN Anast\u00e1cio","year":"2026","unstructured":"Anast\u00e1cio WLDN, Dos Santos TM, Souto FO, Acevedo EO. Mechanism-based management of taxane-induced neuropathic pain in breast cancer survivors: a critical review. Front Pain Res (Lausanne). 2026;7:1717395. https:\/\/doi.org\/10.3389\/fpain.2026.1717395.","journal-title":"Front Pain Res (Lausanne)"},{"key":"1306_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.redar.2018.01.012","volume":"65","author":"A Alc\u00e1ntara Montero","year":"2018","unstructured":"Alc\u00e1ntara Montero A, S\u00e1nchez Carnerero CI. Role of voltage-gated sodium channel blockers in the treatment of chronic pain: potential uses in clinical practice based on available evidence. Rev Esp Anestesiol Reanim (Engl Ed). 2018;65:275\u201383. https:\/\/doi.org\/10.1016\/j.redar.2018.01.012.","journal-title":"Rev Esp Anestesiol Reanim (Engl Ed)"},{"key":"1306_CR11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S1474-4422(17)30005-4","volume":"16","author":"JM Zakrzewska","year":"2017","unstructured":"Zakrzewska JM, Palmer J, Morisset V, Giblin GM, Obermann M, Ettlin DA, et al. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. Lancet Neurol. 2017;16:291\u2013300. https:\/\/doi.org\/10.1016\/S1474-4422(17)30005-4.","journal-title":"Lancet Neurol"},{"key":"1306_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.redare.2025.501858","volume":"72","author":"A Alc\u00e1ntara Montero","year":"2025","unstructured":"Alc\u00e1ntara Montero A. Suzetrigine as a non-opioid analgesic: between need and scientific evidence. Revista Espa\u00f1ola de Anestesiolog\u00eda y Reanimaci\u00f3n (English Edition). 2025;72:501858. https:\/\/doi.org\/10.1016\/j.redare.2025.501858.","journal-title":"Revista Espa\u00f1ola de Anestesiolog\u00eda y Reanimaci\u00f3n (English Edition)"},{"issue":"Suppl 1","key":"1306_CR13","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1097\/j.pain.0000000000003639","volume":"166","author":"EA Gordon","year":"2025","unstructured":"Gordon EA, Tyagi S, Dib-Hajj SD, Bennett DL. Selective targeting of voltage-gated sodium channels to achieve analgesia: current status and future directions. Pain. 2025;166(Suppl 1):S42\u20136. https:\/\/doi.org\/10.1097\/j.pain.0000000000003639.","journal-title":"Pain"},{"key":"1306_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/ACO.0000000000001599","volume":"39","author":"SL Chen","year":"2026","unstructured":"Chen SL, Liu MA, Swisher MW. Suzetrigine, a selective NaV1.8 inhibitor in acute and chronic pain: mechanistic insights, clinical outcomes, and future perspectives. Curr Opin Anaesthesiol. 2026;39:183\u20137. https:\/\/doi.org\/10.1097\/ACO.0000000000001599.","journal-title":"Curr Opin Anaesthesiol"},{"key":"1306_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.750507","volume":"13","author":"H Was","year":"2022","unstructured":"Was H, Borkowska A, Bagues A, Tu L, Liu JYH, Lu Z, et al. Mechanisms of chemotherapy-induced neurotoxicity. Front Pharmacol. 2022;13:750507. https:\/\/doi.org\/10.3389\/fphar.2022.750507.","journal-title":"Front Pharmacol"},{"key":"1306_CR16","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/13543784.2025.2586615","volume":"34","author":"S Di Girolamo","year":"2025","unstructured":"Di Girolamo S, Terribile G, Alberti P, Cavaletti G. Sodium channel modulation as a therapeutic strategy for chemotherapy-induced peripheral neurotoxicity. Expert Opin Investig Drugs. 2025;34:887\u2013903. https:\/\/doi.org\/10.1080\/13543784.2025.2586615.","journal-title":"Expert Opin Investig Drugs"},{"key":"1306_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40263-025-01244-x","volume":"40","author":"C Banh","year":"2026","unstructured":"Banh C, Sic A, Knezevic NN. Sodium channel inhibitors in clinical development for pain management: a focused review. CNS Drugs. 2026;40:165\u201380. https:\/\/doi.org\/10.1007\/s40263-025-01244-x.","journal-title":"CNS Drugs"},{"key":"1306_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70414","volume":"18","author":"R Rajasingham","year":"2025","unstructured":"Rajasingham R, Qi Y. Suzetrigine, a non-opioid small-molecule analgesic: mechanism of action, clinical, and translational science. Clin Transl Sci. 2025;18:e70414. https:\/\/doi.org\/10.1111\/cts.70414.","journal-title":"Clin Transl Sci"},{"key":"1306_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.nrl.2020.02.004","volume":"36","author":"A Alc\u00e1ntara Montero","year":"2021","unstructured":"Alc\u00e1ntara Montero A, S\u00e1nchez Carnerero CI. Voltage-gated sodium channel blockers: new perspectives in the treatment of neuropathic pain. Neurologia. 2021;36:169\u201371. https:\/\/doi.org\/10.1016\/j.nrl.2020.02.004.","journal-title":"Neurologia"},{"key":"1306_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-024-01108-x","volume":"24","author":"M Alsaloum","year":"2025","unstructured":"Alsaloum M, Dib-Hajj SD, Page DA, Ruben PC, Krainer AR, Waxman SG. Voltage-gated sodium channels in excitable cells as drug targets. Nat Rev Drug Discov. 2025;24:358\u201378. https:\/\/doi.org\/10.1038\/s41573-024-01108-x.","journal-title":"Nat Rev Drug Discov"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01306-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01306-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01306-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:28:33Z","timestamp":1786948113000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01306-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1306"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01306-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author has no competing interests to declare.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No datasets were generated or analyzed during the current opinion.","order":4,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Antonio Alc\u00e1ntara Montero conceived the study, collected and analyzed the data, and wrote the manuscript. The author reviewed and approved the final version.","order":6,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}